Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Amyris Inc (AMRSQ)

OTC Markets
Currency in USD
Disclaimer
0.01
0.00(150.00%)
Closed
After Hours
0.00-0.01(-60.00%)

AMRSQ Comments

damnnnnnnn i’m done with penny stocks
it's been a long time, old friend 😎
if it breaks.70, it goes to .50 in a hurry
Bottom is in?
Buy dip lest go to 12 tjis year
you meen 1.2
this is nonsense
wow small cap stocks really going towards ******
Wow... no bouncing anymore... sigh...
Isn't JV supposed to be positive? Why is stock crashing? Thanks.
$400M dilution
can we double from here?
https://investors.amyris.com/2021-08-19-Amyris-Launches-Terasana-Clinical-Clean-Skincare-Brand
Good discount
Buying opportunity in red sea of the market
pre markit?
when this chop is over .. this share will be a great opportunity.
the market is trying to drive us crazy.!!!! this drop this is not explained ..
An Astonishing Beat on revenue  and EPS this morning. EPS +.035 vs. forecast of -.02 and quarterly revenue of $177million vs. forecast of $73.36Mil. That's 507.62% increase in sales YOY
I see big companies have profits the Q1 and to falling 20% .. and I'm scared for tomorrow.
Stock Price ForecastThe 5 analysts offering 12-month price forecasts for Amyris Inc have a median target of 25.00, with a high estimate of 35.00 and a low estimate of 17.00. The median estimate represents a +30.82% increase from the last price of 19.11.https://money.cnn.com › quote › for...
DJ DSM Buys Amyris's Flavor and Fragrance Business for Up to $300 Mln 13/31/2021, 2:19:00 AMListen to the newsAbout 1 min, 16 secondsBy Adria CalatayudKoninklijke DSM NV said Wednesday that it has agreed to acquire Amyris Inc.'s flavor and fragrance intermediates business for up to $300 million.The Dutch nutrition and materials company said it is paying $150 million upfront and further earnout payments estimated at between $100 million and $150 million.DSM in recent years acquired Amyris's Farnesene business as well as its Brotas biotechnology manufacturing facilities in Brazil. DSM and California-based Amyris will continue their research-and-development partnerships, the Dutch company said.DSM said the deal extends its offerings in aroma ingredients for the flavor-and-fragrance and cosmetics industries and strengthens its sustainability profile further as bio-based flavor and fragrance ingredients offer additional alternatives to chemistry-based products as well as botani
The vultures are here
Beat earnings expectations. Great news!
WooHoo!
Is it ever gooing to stop? IMO it should have dropped several times
No, I'm sure that this company is going to be skyrocketed continuously. This has a lot of potential.
The long term bottom is in.
time to fall back to $3 level.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.